WO1995005852A1 - Agent de traitement d'etats de sensibilite, d'hyperreactivite et d'hypoactivite de la peau, de formes d'acne, de dermatites atopiques, du psoriasis, du prurigo, de photodermatoses, de l'ichtyose et d'infections virales - Google Patents

Agent de traitement d'etats de sensibilite, d'hyperreactivite et d'hypoactivite de la peau, de formes d'acne, de dermatites atopiques, du psoriasis, du prurigo, de photodermatoses, de l'ichtyose et d'infections virales Download PDF

Info

Publication number
WO1995005852A1
WO1995005852A1 PCT/EP1994/002831 EP9402831W WO9505852A1 WO 1995005852 A1 WO1995005852 A1 WO 1995005852A1 EP 9402831 W EP9402831 W EP 9402831W WO 9505852 A1 WO9505852 A1 WO 9505852A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
acid
skin
active
forms
Prior art date
Application number
PCT/EP1994/002831
Other languages
German (de)
English (en)
Inventor
Reza Keyhani
Ghita LANZENDÖRFER
Gerhard Sauermann
Uwe SCHÖNROCK
Franz STÄB
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to EP94925480A priority Critical patent/EP0721347A1/fr
Priority to JP7507355A priority patent/JPH09501925A/ja
Publication of WO1995005852A1 publication Critical patent/WO1995005852A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention relates to active ingredients and preparations, in particular for topical use, in particular for the prophylaxis and treatment of sensitive, hyper-reactive and skin predisposed to dermatids, acne forms, as well as deficient or hypoactive aging skin and for the treatment of overt atopic dermatids such as e.g. Atopic dermatitis, neurodermatitis, atopic dermatitis and seborrhoeic dermatitis and light-induced dermatoses (e.g. Monica acne and in particular polymorphic ichthermatosis, photodermatitis), prurigo forms, pruritus, psoriasis forms, ichthyosis and viral infections such as z. B. herpes simplex, herpes zoster or herpes labialis.
  • the object of the invention is to improve this unsatisfactory state of the art and to provide cosmetic, dermatological and / or pharmaceutical active substances and preparations which contribute to the prophylaxis and treatment of sensitive hyper-reactive skin prone to dermatitis and to the prophylaxis and treatment serve the above-mentioned manifest dermatoses without inducing the side effects of known agents, even with long-term use.
  • the invention relates to the use of a compound or more compounds from the group of antioxidants and / or an active substance or more active substances from the group of active substances which regulate the endogenous energy metabolism and / or the endogenous enzymatic antioxidant system, in particular that of Skin, regulate to a normal level or maintain a normal level, for the prophylaxis and treatment of sensitive, hyperreactive and predisposed skin for dermatids, acne forms, deficient or hypoactive aging skin and of manifest atopic dermatids such as, for example Atopic dermatitis, neurodermatitis, atopic eczema and seborrhoeic dermatitis and light-induced dermatoses such as e.g. Polymorphic light eruption, noir acne, photodermatitis, as well as prurigo forms,
  • the invention also relates to the use of preparations, in particular topical preparations, containing one or more compounds Compounds from the group of enzymatic and / or non-enzymatic antioxidants and / or one or more active substances from the group of active substances which regulate the endogenous energy metabolism and / or the endogenous enzymatic antioxidant system, in particular that of the skin, to a normal level or maintain a normal level, for the prophylaxis and treatment of sensitive, hyper-reactive skin predisposed to dermatids, acne forms, deficient or hypoactive aging skin and of manifest atopic dermatids such as, for example, atopic dermatitis, neurodermatitis, atopic eczema and seborrhoeic dermatitis and dermatitis such asidos acne, photodermatitis and in particular polymorphic light dermatosis as well as prurigo forms, pruritus forms, psoriasis forms, rosacea, ichthyosis and viral infections
  • the invention furthermore relates to the use of combinations of:
  • one or more active substances from the group of active substances which regulate or maintain the endogenous energy metabolism and / or the endogenous enzymatic antioxidant system, in particular that of the skin, to a normal level, and
  • antimicrobial principles of action in particular anti-bacterial and / or antifungal and / or antiviral principles of action
  • atopic dermatids such as, for example, atopic dermatitis, neurodermatitis, atopic eczema and seborrheic dermatitis, seborrheic eczema and pruritus forms, psoriasis forms, ichthyosis and viral infections, in particular herpes infections.
  • the invention furthermore relates to the use of combinations of:
  • an active ingredient or several active ingredients from the group of active ingredients which regulate the endogenous energy metabolism and / or the endogenous enzymatic antioxidant system, in particular that of the skin, to a normal level or maintain a normal level, and
  • corticosteroids for the prophylaxis and treatment of all of the aforementioned skin conditions and diseases.
  • the invention also relates to the use of preparations, in particular topical preparations, containing a combination with antimicrobial active principles or one or more antimicrobial active ingredients or with a combination with one or more corticosteroids for prophylaxis or treatment of all of the above skin conditions or diseases.
  • preparations in particular topical preparations, containing a combination with antimicrobial active principles or one or more antimicrobial active ingredients or with a combination with one or more corticosteroids for prophylaxis or treatment of all of the above skin conditions or diseases.
  • the invention furthermore also relates to the combinations of the active compounds according to the invention, in particular the combinations AF and 1-13 and their combinations with one another.
  • Endogenous energy metabolism includes e.g. the pentose phosphate cycle, the beta oxidation of fatty acids and the citrate cycle.
  • Endogenous enzymatic antioxidants or antioxidant systems include e.g. the glutathione redox system and the thioredoxin redox system and the superoxide dismutase system, cytochrome P450 system, monooxygenases and the catalase system.
  • the antiviral or antimicrobial principles of action include, for. B. acyclovir, or gentian violet, ammonium tumenol, tyrotricin / cetylpyridinium chloride, degualinium chloride, aluminum chloride, chlorhexidine gluconate, quinoline, thymol, policresules, wool wax acids and their derivatives, lanthabiotics (eg nisin), triclosanin Minocycline, doxycycline, tetracycline, omega and / or alpha-hydroxycarboxylic acids, eg Fruit acids and especially omega and / or alpha-hydroxy fatty acids (e.g.
  • BC- to C, -chain hydroxy fatty acids as well as gamma-linolenic acid, linoleic acid and their esters with alcohols (e.g. monoglycerol, diglycerol, triglycerol esters, ethyl, methyl -, propyl, isopropyl, butyl ester), witch hazel extract, salicylic acid and its derivatives, sulfonamides and antimycotics such as.
  • alcohols e.g. monoglycerol, diglycerol, triglycerol esters, ethyl, methyl -, propyl, isopropyl, butyl ester
  • witch hazel extract e.g. monoglycerol, diglycerol, triglycerol esters, ethyl, methyl -, propyl, isopropyl, butyl ester
  • witch hazel extract e.g. monoglycerol, digly
  • Preferred corticosteroids are: e.g. A cinonid, dexamethasone, triamcinolone and derivatives,
  • Betamethasone and derivatives, flumethasone and derivatives are preferred.
  • the amount of corticosteroids in the preparations is preferably 0.001 to 5% by weight, in particular 0.01 to 1% by weight, based on the total weight of the preparations.
  • the active substances and combinations and preparations according to the invention in particular after topical application to human skin, for the prophylaxis and treatment of the above-mentioned dermatoses and the sensitive, hyper-reactive and predisposed to dermatids Skin can serve and that the inventive combinations of antioxidants and / or active substances that affect the endogenous energy metabolism, especially in the skin achieve a synergistic effect with antimicrobial active principles or corticosteroids.
  • Oxidative, radical stress is caused, for example, by ozone, UV light, smog, cigarette smoke, oxidative chemical agents and possibly also by infections with pathogenic germs.
  • ozone UV light
  • smog smog
  • cigarette smoke oxidative chemical agents
  • oxidative chemical agents possibly also by infections with pathogenic germs.
  • the mechanism of action of the new active substances and preparations according to the invention has not yet been completely clarified. It is assumed that the cause of the deficient or pathological skin conditions in question is increased oxidative, radical stress, which is alleviated by the treatment with the active compounds according to the invention or even regulated to the normal level of intact and healthy skin. It is also advantageous that the active ingredients used according to the invention also support the enzymatic antioxidant and repair systems and the endogenous energy metabolism of the skin, so that there is an additive or even synergistic mechanism of action in the active systems and preparations used according to the invention.
  • active ingredients can reach the site of action on the surface of the skin, mucous membrane and / or skin appendages or by penetration via the sebum and sweat glands, but also along hair shafts or through the stratum corneum.
  • certain active substances according to the invention eg antimicrobial active substances
  • in the preparations according to the invention for. B. be prevented by coupling to specific carriers from penetrating into the skin, so that only a superficial effect on the skin and / or hair and / or in the sebum and / or sweat glands and / or the hair shafts is achieved.
  • penetration promoters such.
  • DMSO azones, unsaturated fatty acids (e.g. oleic acid, ice-alkene fatty acids), heptadecenoic acid, liposomes, nanosomes, microsomes, niosomes etc. are added or the active ingredients are packaged in them to achieve a sustained release and / or preservation effect.
  • unsaturated fatty acids e.g. oleic acid, ice-alkene fatty acids
  • heptadecenoic acid e.g. oleic acid, ice-alkene fatty acids
  • atopic eczema, seborroic eczema, rosacea, ichthyosis, acne and psoriasis forms and viral infections such as.
  • B. herpes simplex, herpes labialis and herpes zoster, antimicrobial and / or antiviral active principles or Korti ⁇ costeroids can be used in combination with the antioxidant and / or the endogenous energy metabolism regulating systems.
  • Preferred antioxidants according to the invention are:
  • L-amino acids e.g. from glycine, histidine, tyrosine, tryptophan, phenylalanine, methionine, glutamic acid, arginine, serine
  • derivatives e.g. hydroxyl, methyl, ethyl compounds
  • imidazoles e.g. urocanic acid
  • peptides with a proportion of L-histidine such.
  • D L-carnosine, D-carnosine, L-carnosine and their derivatives (for example anserine, L-alanylhistidine, L-histidyltryptophane, L-methionylhistidine, L-histidyltyrosyl-tryptophan, methionyltryptophan) and / or one Proportion of tryptophan (e.g. L-glycyltryptophan, L-tryptophanylhistidine, L-methionyltryptophan), polyamines (e.g. spermine, spermidine), carotenoids, carotenes (e.g.
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl- , Methyl, ethyl, propyl, ayl, butyl and lauryl, palmitoyl, oleyl, gamma-linoleyl, cholesteryl and glyceryl esters) and their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and their derivatives (oxidized and / or reduced forms, esters, Ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g.
  • buthionine sulfoximines e.g. homocysteine sulfoximine, buthionine sulfones, pentate, hexa-, heptahionine sulfoximine
  • very low tolerable doses e.g. pmol to mmol / kg.
  • metal chelators e.g. alpha-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • alpha-hydroxy acids e.g. citric acid, lactic acid, malic acid, salicylic acid, glyoxylic acid
  • humic acid e.g. citric acid, lactic acid, malic acid, salicylic acid, glyoxylic acid
  • humic acid e.g.
  • cholic acid Glucocholic acid, taurocholic acid, taurine
  • bile extracts bilirubin, biliverdin, EDTA, EGTA and their derivatives as well as unsaturated fatty acids and their derivatives (eg gamma-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol or their Derivatives, vitamin C and derivatives (e.g. ascorbyl palmitates, Mg - ascorbyl phosphates, ascorbylacetates), tocotrienols, tocopherols and their derivatives (e.g.
  • vitamin E - acetate, alpha, beta, gamma, delta tocopherols vitamin A and derivatives (retinol , Vitamin A - palmitate, vitamin A - acid) and konyferyl benzoate of the benzoin, flavonoids and their derivatives z.
  • rutinic acid and its derivatives e.g.
  • ZnO, ZnSO. selenium and its derivatives (e.g. selenomethionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-stilbene oxide), calcium and magnesium and their Derivatives (e.g. Cacl_, Mgcl_> and the derivatives suitable according to the invention (salts, esters, ethers, alcohols, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients.
  • selenomethionine e.g. selenomethionine
  • stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
  • calcium and magnesium and their Derivatives e.g. Cacl_, Mgcl_> and the derivatives suitable according to the invention (salts, esters, ethers, alcohols, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients
  • the plant extracts and cell extracts mentioned are known or can be obtained by known processes and are also commercially available.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001% by weight to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the preparation, especially the topical preparation.
  • Preferred active substances according to the invention which regulate the endogenous energy metabolism and / or the endogenous enzymatic antioxidant system, in particular that of the skin, to a normal level or maintain a normal level, for example vitamin D and its derivatives (eg vitamin D ..), D. -Biotin and its derivatives (e.g. biotinethyl, methyl, butyl, propionyl, isopropionyl ester, biocytin), glucose and glucose derivatives (e.g.
  • the amount of these regulating agents is e.g. 0.0001% by weight to 30% by weight, preferably 0.01% by weight to 20% by weight, in particular 0.1% by weight to 10% by weight, in each case based on the total weight of the preparations , in particular topical preparations.
  • Combinations of one or more of the compounds from the group of antioxidants with one or more compounds of the group of substances which regulate or normalize energy metabolism according to the invention are particularly preferred.
  • the amount of the combinations according to the invention and the effective combination according to the invention of the antioxidants with active ingredients for supporting and regulating the energy metabolism in the preparations is preferably 0.001% by weight to 40% by weight, preferably from 0.01% by weight to 30 % By weight, in particular 0.1% by weight to 15% by weight, based on the total weight of the preparation, in particular topical preparation.
  • Atopic dermatitis, neurodermatitis, atopic eczema, seborrhoeic eczema, forms of psoriasis, forms of acne, prurigo, pruritus and rosacea preferred antimicrobial systems are: Antibactericides and antibacterial agents such.
  • Gentian violet ammonium tumenol, tyrotricin / cetylpyridinium chloride, dequalinium chloride, aluminum chloride, chlorhexidine gluconate, quinolinol, thymol, policresules, wool wax acids and their derivatives, lanthabiotics (such as nisin), triclosan, minocycline, doxycycline, doxycycline and / or hydroxycarboxylic acids ⁇ e.g. fruit acids and in particular omega and / or alpha-hydroxy fatty acids (e.g.
  • C-- to C_ fi -chain hydroxy fatty acids as well as gamma-linolenic acid, linoleic acid and their esters with alcohols (e.g. monoglycerol, diglycerol , Triglycerol ester, ethyl, methyl, propyl, isopropyl, butyl ester), witch hazel extract, salicylic acid and its derivatives, sulfonamides and antifungals such as.
  • alcohols e.g. monoglycerol, diglycerol , Triglycerol ester, ethyl, methyl, propyl, isopropyl, butyl ester
  • witch hazel extract e.g. monoglycerol, diglycerol , Triglycerol ester, ethyl, methyl, propyl, isopropyl, butyl ester
  • witch hazel extract e.g. monoglycerol, diglycerol , Tri
  • clotrimazole econazole, oxiconazole, miconazole, ketoconazole, isoconazole
  • griseofulvin terbinafine, nystatin, amphotericin and / or undecylenic acid.
  • the amount of the active combination of the antioxidants and / or active ingredients according to the invention for supporting and regulating the energy metabolism in the preparations is preferably from 0.0001% to 40% by weight, preferably from 0.01% by weight up to 30% by weight, in particular 0.1% by weight to 15% by weight, based on the total weight of the preparation.
  • the topical preparations are preferred in each case.
  • the amount of the antimicrobial active principles in the preparations with the combinations mentioned above is preferably 0.0001% by weight, preferably 0.0005% by weight, in particular 0.001% by weight, based on the total weight of the preparation .
  • the topical preparations are preferred in each case.
  • the following active substances and combinations of active substances and preparations are preferred.
  • the amounts of weight given there are particularly preferred amounts by weight, based on the total weight of the preparations, with topical preparations being preferred.
  • the substances are used to treat the skin symptoms and diseases mentioned above:
  • Cystine 0.05-15% by weight
  • biocytin 0.001-0.8%
  • niacic acid 0.001-2.5% by weight
  • thymol 0.005-2.1% by weight
  • Cystamine (0.01-5.0% by weight), L-histidine (0.01-6% by weight), ⁇ -carotene (0.01-3% by weight), ascorbyl palmitate
  • L-anserine (0.01-3.2% by weight), palmitoylthioredoxin (0.002-0.5% by weight), butylated hydroxyanisole (0.05-0.9% by weight), heptadecenoic acid (0.01- 0.9% by weight), linoleyl cysteine (0.01-1.8% by weight), humic acid (0.01-2.7% by weight), ATP (0.004-0.5% by weight), biotin ethyl ester ( 0.005 - 0.9 wt.
  • Lycopene (0.01-3.8% by weight), L-carnosine (0.01-15% by weight), glycine (0.02-1.2% by weight), lipoic acid (0.01- 1.8% by weight), FADH_ (0.0008-0.5% by weight), palmitic acid (0.01 - 2.5 wt%), Mg ascorbyl phosphate (0.002 - 5.4 wt%), ethyl cysteine (0.004 - 4.5 wt%), cholesteryl cystine (0.02
  • vitamin E palmitate 0.02 - 8.6% by weight
  • vitamin A oleate 0.02 - 2.0% by weight
  • reduced thiols such as.
  • Peptide compounds according to the invention (0.001-14% by weight) and their compounds with the active ingredients mentioned under 1-8, in particular with di- and / or tripeptide compounds, which contain the amino acids histidine, tryptophan, tyrosine, methionine, glutamic acid contain (e.g. L-alanylhstidine, L-glycyl-histidine, L-histidyl-tryptophan, L-histidylmethionine, Se-methionylhstidine) and / or polyamines such as.
  • Fatty acids and lipid compounds (0.0005-12% by weight) which are active according to the invention and / or their compounds with the active substances mentioned under 1-9 (eg lauryl, oleyl, linoleyl, palmitoyl, stearyl - and cholesteryl, furan compounds) and combinations of the above-mentioned substances each with the mentioned active systems 1-9.
  • nucleic acid compounds and nucleotide compounds (0.0001-7% by weight) which are active according to the invention and their compounds with the active substances mentioned under 1-10
  • Enzymatic antioxidant systems effective according to the invention such as. B. the enzymes superoxide dismutase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, oxidoreductases (z. B.
  • glucose-6-phosphate - dehydrogenase succinate dehydrogenase, malate dehydrogenase, especially the NAD -, NADP - and FAD + reductases and carboxylases (eg biotin carboxylase, acetyl-CoA carboxylase), cytochrome P 450 reductase, cytochrome P450 monooxygenases, monoamine oxidase and in particular the coenzymes effective according to the invention (0.0001-5% by weight) and their precursors (e.g. provitamins, vitamins) to the enzymes mentioned such.
  • biocytin, D-biotin and its derivatives z. B.
  • aminopterin, tetrahydropterin), coenzyme Q and its derivatives e.g. ubiquinol
  • vitamin D and their derivatives e.g. vitamin D -.
  • suitable derivatives salts, sugars, esters, alcohols, ethers, nucleotides, nucleos ide, peptides and lipids
  • Antimicrobial active systems such as a) antibactericidal and antibacterial active ingredients in their effective concentrations such as. B. gentian violet, ammonium tumenol, tyrotricin / cetylpyridinium chloride, dequalinium chloride, aluminum chloride, chlorhexidine gluconate, quinolinol, thymol, policresules, wool wax acids and their derivatives, lanthabiotics (e.g. nisin), triclosan, minocyclinetracycline, doxycycline, doxin omega and / or alpha Hydroxycarboxylic acids, e.g.
  • fruit acids and in particular omega and / or alpha-hydroxy fatty acids e.g. BC,. To C., -chain hydroxy fatty acids
  • omega and / or alpha-hydroxy fatty acids e.g. BC,.
  • -chain hydroxy fatty acids as well as gamma-linolenic acid, linoleic acid and their esters with alcohols (e.g. monoglycerol, diglycerol -, Triglycerol ester, ethyl, methyl, propyl, isopropyl, butyl ester), witch hazel extract, salicylic acid and its derivatives, sulfonamides, and b) and antifungal agents in their effective concentrations, such as, for. B.
  • alcohols e.g. monoglycerol, diglycerol -, Triglycerol ester, ethyl, methyl, propyl, isopropyl, butyl ester
  • witch hazel extract
  • imidazole derivatives eg clotrimazole, econazole, oxiconazole, miconazole, ketoconazole, isoconazole
  • griseofulvin terbinafine, nystatin, terbinafine, amphotericin and / or undecylenic acid.
  • Combinations according to the invention with the antimicrobial active systems and active ingredients listed under point 13 are preferably used for the treatment of the skin conditions and diseases according to the invention, but in particular for atopic dermatitis, neurodermatitis, atopic eczema, seborrheaic eczema, psoriasis forms, acne forms, prurigo, pruritus and rosacea.
  • the preparations according to the invention can contain one or more of the combinations 1-13 mentioned above.
  • the active compounds according to the invention and in particular the active compound systems 1-13 with urea (for example 0.01-15% by weight, based on the entire preparation).
  • One or more of the active ingredients and combinations according to items 1-12 are particularly preferably combined with one or more of the active ingredients and combinations of item 13.
  • the amounts of weight given there are particularly preferred amounts of weight and in each case relate to the total weight of the preparations.
  • the substances of the preparations from A-F can preferably also be used in amounts which are within the weight ranges, also in each case based on the total weight of the preparations.
  • the upper limit values of these weight ranges are then preferably ten times the respectively stated weight% value of the substances in A-F.
  • the associated lower limit values are then preferably one tenth of the corresponding weight% value of the substances in A-F.
  • Combinations for the treatment and prophylaxis of atopic dermatids can e.g. be composed of the following individual substances and their derivatives, the weight quantities as described above being preferred and also defining ranges:
  • Combination A carnosine 3.0% by weight, L-histidine 0.8% by weight, trans - urocaninic acid 2.0% by weight, ß-carotene 0.5% by weight, cystine 0.2% by weight , Mg-Ascor-bylpalmitate 2.0% by weight, Vitamin E acetate 3.5% by weight, wool wax acids 0.2% by weight, glucosylcystamine 0.04% by weight, oleic acid 0.3% by weight, Heptadecenoic acid 0.02% by weight, GTP 0.05% by weight, FADH 2 0.02% by weight, glucose-6-phosphate 0.06% by weight, NADPH 0.05% by weight, GSSG 0.5% by weight .%, Ubiquinol 0.1% by weight, cAMP 0.1% by weight, ATP 0.05% by weight.
  • psoriasis e.g. the following combination B, e.g. can be composed of the following individual substances and their derivatives and the weight quantities as described above are preferred and also define ranges:
  • Combination B carnosine 2.0% by weight, L - histidine 0.5% by weight, L - tryptophan, 0.4% by weight, rutinic acid 0.8% by weight, oleic acid 0.3% by weight, ethyl cysteine 0.5 % By weight, glutathione (GSH) 0.1% by weight, vitamin E acetate 3.0% by weight, vitamin A dipalmitate 1.4% by weight, cucumberaceen extract 0.8% by weight.
  • GSH glutathione
  • combination C which can be composed of the following individual substances and their derivatives and where the amounts by weight as described above are preferred and also define ranges:
  • Combination C oleylcarnosine 2.8% by weight, cholesterylcystine 0.4% by weight, oleylcysteine 0.2% by weight, ß-carotene 0.8% by weight, citric acid 1.4% by weight, glutamylcysteine 0.05% by weight %, Glutamic acid 0.5% by weight, glutathione (GSH) 0.05% by weight, vitamin E palmitate 4.5% by weight, lipoic acid 0.5% by weight, L-carnosine 1.8% by weight, L Arginyltryptophan 0.3% by weight,.
  • GSH glutathione
  • photodermatoses e.g. the following combination D, which can be composed of the following individual substances and their derivatives, and the weight quantities as described above are preferred and also define ranges:
  • Combination D glycosyl rutin 1.0% by weight, D, L-carnosine 2.7% by weight, cystine 1.1% by weight, L-histidine 0.5% by weight, L-tyrosine 0.2% by weight .%, L-tryptophan 0.6% by weight, methionine 0.9% by weight, vitamin E acetate 2.0% by weight, folic acid 0.5% by weight, mannose 0.5% by weight, malic acid 2 , 0% by weight, glycine 0.2% by weight, oleic acid 0.3% by weight, uric acid 0.05% by weight, glutathione (GSH) 0.08% by weight, NADPH 0.02% by weight, Mg ascorbyl palmitate 3.5% by weight, pyruvate 0.07% by weight.
  • GSH glutathione
  • the combination E which is composed of the following individual substances and their derivatives can be and the weight quantities as described above are preferred and also define ranges:
  • Combination E mannosyl rutin 1.8% by weight, L-alanylhistidine 0.08% by weight, methionine 1.6% by weight, glutathione (GSH) 0.4% by weight, L-serine 0.9% by weight, D-biotin 0.2% by weight, citric acid 0.5% by weight, lactic acid 0.1% by weight, malic acid 0.3% by weight, coffee acid 0.2% by weight, glutamic acid 0.5% by weight, Pantothenic acid 0.3% by weight, vitamin E nicotinate 0.5% by weight, salicylic acid 0.8% by weight, witch hazel extract 0.3% by weight, tannic acid 1.1% by weight, thiamine 0.3% by weight , Oleic acid 0.3 wt.
  • B. can be composed of the following individual substances, is particularly suitable and the weight quantities as described above are preferred and also define ranges:
  • Combination F selenium methionine 0.05% by weight, L-arginine 1.2% by weight, L-lysine 1.0% by weight, tetrahydrofolate 0.05% by weight, biocytin 0.15% by weight, L-methionine 1.1% by weight, adenine 0.2% by weight, guanine 0.1% by weight, flavin mononucleotide (FMN) 0.1% by weight, niacinic acid 0.3% by weight, citric acid 1.0% by weight, glucose -6-phosphate 0.1% by weight, glyceraldehyde-3-phosphate% by weight, ferulic acid 1.4% by weight, vitamin A palmitate 0.4% by weight, vitamin E nicotinate 0.3% by weight, L-anserine 0.3% by weight, serine phosphate 0.02% by weight.
  • the combinations of these active substances according to F with the active systems 1, 4 to 12 have also proven to be particularly advantageous for the prophylaxis and treatment of hypoactive or deficient skin and aging skin.
  • the combinations A-F are preferably incorporated into topical preparations.
  • the weight percentages given relate in each case to the total weight of the preparations.
  • the active ingredients are administered to reduce the frequency and severity of manifestations of the diseases. Treatment in the manifest stage leads to their shortening and alleviation of the symptoms.
  • the active compounds according to the invention and their combination and the preparations obtained therewith such as pharmaceutical preparations and topical preparations in the form of creams, lotions, gels and sprays as well as solutions (for example aqueous, alcoholic or aqueous-alcoholic) and other suitable formulations are particularly prophylactically active, by protecting sensitive skin predisposed to said dermatoses, in particular in the case of atopic dermatids, or by reducing their formation.
  • the formulations containing the active ingredient are applied once and several times a day on a regular basis.
  • dermatoses especially with atopic dermatids (e.g. atopic eczema, neurodermatitis) and in psoriasis and pruritus, after adequate treatment with the active compounds and preparations according to the invention, there is an improvement in the skin conditions, in particular a reduction in the itchiness which occurs in these dermatoses. Thereafter, further prophylactic treatment can be carried out.
  • atopic dermatids e.g. atopic eczema, neurodermatitis
  • psoriasis and pruritus after adequate treatment with the active compounds and preparations according to the invention, there is an improvement in the skin conditions, in particular a reduction in the itchiness which occurs in these dermatoses. Thereafter, further prophylactic treatment can be carried out.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin, scalp and / or hair in a sufficient amount in the customary manner.
  • the active substances and preparations according to the invention also in combination with conventional active substances and methods which are usually used for the treatment of the dermatoses mentioned (for example cyclosporin A, corticosteroids, psoralen, UV) -Therapy, PUVA therapy, UVA and / or UVB filter, urea, antibiotics, acyclovir).
  • active substances and methods which are usually used for the treatment of the dermatoses mentioned (for example cyclosporin A, corticosteroids, psoralen, UV) -Therapy, PUVA therapy, UVA and / or UVB filter, urea, antibiotics, acyclovir).
  • Topical, cosmetic and dermatological preparations according to the invention can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / 0) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W), oil-in-water-in-oil (0 / W / O), a gel, a solid stick or an aerosol.
  • W / 0 an emulsion of the type water-in-oil
  • O / W oil-in-water-in-oil
  • the topical, cosmetic and can dermato ⁇ logical preparations cosmetic adjuvants of the invention contain, as they are commonly used in 'such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, Farb ⁇ agents, pigments which have a coloring effect, Thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing Substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • topical, cosmetic or dermatological preparation is a solution or lotion, the following can be used as solvents:
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analog products.
  • Water can also be a component of alcoholic solvents
  • Emulsions according to the invention for example in the form of a sunscreen cream or sunscreen milk, are preferred and contain, for example, the fats, oils, waxes and other fat bodies, as well as water and an emulsifier, as is usually used for such a type of formulation.
  • Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, l, 2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickening agent which, in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, preferably in the case of aqueous-alcoholic or alcoholic gels is a polyacrylate.
  • a thickening agent which, in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, preferably in the case of aqueous-alcoholic or alcoholic gels is a polyacrylate.
  • Fixed pins according to the invention contain e.g. natural and / or synthetic waxes, fatty alcohols and / or fatty acid esters. Lip care sticks are preferred.
  • Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • the topical preparations can preferably also contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, is in particular 1.0 to 6.0% by weight on the total weight of the preparations in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
  • the UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances e.g. to call:
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone,
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester,
  • water-soluble substances examples include: - Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself;
  • UVB filters which can be used in combination with the active compounds according to the invention, is of course not intended to be limiting.
  • the invention also relates to the use of a combination of the active compounds according to the invention with at least one UVA and / or UVB filter in a cosmetic or dermatological preparation.
  • the cosmetic and dermatological preparations can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. These combinations of UVA and / or UVB filter and pigment or preparations which contain this combination are also the subject of the invention. The amounts given for the above combinations can be used. Cosmetic preparations which are a skin cleanser or shampoo contain preferably at least one anionic, non-ionic or amphoteric surface-active substance, or else mixtures of such substances, active substances and auxiliaries according to the invention, as are usually used therefor. The surface-active substance or the mixtures of these substances can be present in the shampoo in a concentration between 1% by weight and 50% by weight.
  • cosmetic or dermatological preparations in the form of a lotion which is rinsed out and e.g. before or after decolorization, before or after shampooing, between two shampooing steps, before or after permanent waving, these are e.g. for aqueous or aqueous-alcoholic solutions which may contain surface-active substances, preferably non-ionic or cationic surface-active substances, the concentration of which is between 0.1 and 10% by weight, preferably between 0.2 and 5% by weight. %.
  • These cosmetic or dermatological preparations can also be aerosols with the auxiliaries usually used for them.
  • Preparations for the treatment of the scalp and hair can be present as emulsions which are of the non-ionic or anionic type.
  • nonionic emulsions contain oils or fatty alcohols, which for example can also be polyethoxylated or polypropoxylated, or else mixtures of the two organic components.
  • These emulsions may contain cationic surface-active substances.
  • cosmetic preparations for treating the skin, scalp and hair can be in the form of gels or hair lotions which, in addition to an effective content of Active substances according to the invention and solvents usually used therefor, preferably water, still organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, for example aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distate.
  • the thickener is contained in the gel, for example, in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • compositions which contain the compounds according to the invention or their derivatives or pharmaceutically acceptable salts together with a pharmaceutically acceptable diluent or carrier are also provided as preparations.
  • the compounds of the present invention can also be administered orally or parenterally in humans e.g. in a dosage of 0.01 to 5000 mg, preferably 1 to 500 mg, per day, in particular also in divided doses, for example twice to four times a day.
  • the active compounds according to the invention can be mixed with customary pharmaceutically acceptable diluents or carriers and, if appropriate, with other auxiliaries and administered, for example, orally or parenterally. They can preferably be taken orally in the form of granules, capsules, pills, tablets, film-coated tablets, dragées, syrups, emulsions, suspensions, dispersions, aerosols and solutions and liquids, or else as suppositories, vaginal balls or parenterally, for example in the form of solutions, emulsions or Suspensions are administered. Oral preparations can be one or contain other additives such as sweeteners, flavoring agents, colorants and preservatives.
  • Tablets can contain the active ingredient mixed with customary pharmaceutically compatible auxiliaries, for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.
  • auxiliaries for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.
  • Suitable carriers are, for example, milk sugar (lactose), gelatin, corn starch, stearic acid, ethanol, propylene glycol, ether of tetrahydrofurfuryl alcohol and water.
  • the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. If water is used as the diluent, organic solvents can optionally be used as auxiliary solvents.
  • tablets can of course also contain additives, such as sodium citrate, calcium carbonate and dicalzium phosphate, together with various additives, such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned.
  • Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
  • the active compounds can be used in addition to above-mentioned auxiliaries with various flavor enhancers or colorants.
  • solutions of the active ingredients can be used using suitable liquid carrier materials.
  • Capsules can contain the active ingredient as a single component or mixed with a solid diluent such as calcium carbonate, calcium phosphate or kaolin.
  • the injectable preparations are also formulated in a manner known per se.
  • the pharmaceutical preparations can contain the active ingredient in an amount of 0.1 to 90 percent by weight, in particular 1-90 percent by weight. Capsules are particularly preferred.
  • the active compounds preferably contain individual doses in an amount of 0.01 mg - 500 mg.
  • the invention also relates to pharmaceutical and topical preparations which are characterized in that they contain a combination of antioxidants and regulating active substances according to the invention and the combination of antioxidants and / or regulating active substances according to the invention with antiviral and / or antimicrobial active principles as described above described.
  • Combination A carnosine 3.0 parts by weight, histidine 0.8 parts by weight, urocanic acid 2.0 parts by weight, ⁇ -carotene 0.5 parts by weight, cystine 0.2 parts by weight -T., Mg ascorbyl palmitate 2.0 parts by weight, Vitamin E acetate 3.5 parts by weight, oleyl glutathione 0.2 parts by weight, glucosylcystamine 0.04 parts by weight, oleic acid 0. 3 parts by weight, heptadecenoic acid 0.02 parts by weight, GTP 0.05 parts by weight, FADH 0.02 parts by weight, glucose 6-phosphate 0.06 parts by weight , NADPH 0.05 part by weight, GSSG 0.5 part by weight. , Ubiquinol 0.1 part by weight, cAMP 0.1 part by weight, ATP 0.05 part by weight
  • Combination B ' carnosine 2.0 parts by weight, L-histidine 0.5 parts by weight, L-tryptophan 0.4 parts by weight, rutinic acid 0.8 parts by weight , Oleic acid 0.3 part by weight, ethyl cysteine 0.5 part by weight, glutathione 0.1 part by weight, vitamin E acetate 3.0 parts by weight, vitamin A palmitate 1.4 Parts by weight, cucumberaceen extract 0.8 parts by weight.
  • Combination C oleyl carnosine 2.8 parts by weight, cholesteryl cystine 0.4 parts by weight, oleyl cysteine 0.6 parts by weight, ß-carotene 0.8 parts by weight, citric acid 1.4 parts by weight .-T., Glutamylcysteine 0.05 parts by weight, glutamic acid 0.5 parts by weight, glutathione (GSH) 0.05 parts by weight, vitamin E palmitate 4.5 parts by weight, Lipoic acid 0.5 part by weight, L-carnosine 1.8 part by weight, L-arginine tryptophan 0.3 part by weight
  • Combination D ' glycosyl rutin 1.0 part by weight, D, L-carnosine 2.7 part by weight, cystine 1.1 part by weight, L-histidine 0.5 part by weight, L-tyrosine 0.2 part by weight, L-tryptophan 0.6 part by weight, methionine 0.9 part by weight , Vitamin E acetate 2.0 parts by weight, folic acid 0.5 parts by weight, mannose 0.5 parts by weight, malic acid 2.0 parts by weight, glycine 1.2 parts by weight T., oleic acid 0.3 part by weight, uric acid 0.05 part by weight, glutathione (GSH) 0.08 part by weight, NADPH 0.02 part by weight, Mg ascorbyl palmitate 3.5 part by weight, pyruvate 0.07 part by weight.
  • GSH glutathione
  • Combination E ' mannosyl rutin 1.8 parts by weight, L-alanylhstidine 0.08 parts by weight, methionine 1.6 parts by weight, glutathione (GSH) 0.4 parts by weight, L -Serine 0.9 part by weight, D-biotin 0.2 part by weight, citric acid 0.5 part by weight, lactic acid 0.1 part by weight, malic acid 0.3 part by weight -T, coffee acid 0.2 part by weight, glutamic acid 0.5 part by weight, pantothenic acid 0.3 part by weight, vitamin E - nicotinate 0.5 part by weight, salicylic acid 0.8 part by weight -T., Hamame- lis extract 0.3 parts by weight, tannic acid 1.1 parts by weight, thiamine 0.3 parts by weight, oleic acid 0.3 parts by weight.
  • Combination F ' selenium methionine 0.05 parts by weight, L-arginine 1.2 parts by weight, L-lysine 1.0 parts by weight, tetrahydrofolate 0.05 parts by weight, biocytin 0 , 15 parts by weight, L-methionine 1.1 parts by weight, adenine 0.2 parts by weight, guanine 0.1 parts by weight, flavin mononucleotide (FMN) 0.1 parts by weight T., niacic acid 0.3 part by weight, citric acid 1.0 part by weight, glucose-6-phosphate 0.1 part by weight, glyceraldehyde-3-phosphate 0.2 part by weight , Ferulic acid 1.4 parts by weight, Vitamin A palmitate 0.4 parts by weight, Vitamin E nicotinate 0.3 parts by weight, L-anserine 0.3 parts by weight, serine phosphate 0.02 part by weight.
  • FMN flavin mononucleotide
  • Aqueous preparation (facial toner)
  • PPG-3 myristyl ether (Witconol APM) 1,000
  • Acrylic acid polymer (Carbopol 934) 1,000
  • Ceteareth-25 (Cremophor A25) 1,500 Cetearyl Alcohol (Lanette 0) 8,500 combinations A '+ C A' 26.4 C 13.2
  • Ceteareth-25 (Cremophor A25) 2,000 cetearyl alcohol (Lanette 0) 8,000 petroleum jelly, DAB 9 10,000 mineral oil, DAB 9 10,000 combination D 1 : 31.6 panthenol 1.00 caffeic acid 0.50 glutathione peroxidase 0.002 water VES ad 100,000
  • Ceteareth 25 (Cremophor A25) 2,000 cetearyl alcohol (Lanette 0) 3,000 mineral oil, DAB 9 5,000 propylene glycol 3,000 polyvinylpyrrolidone 0.500 combination A ', B' and D 1 A ': 14.75
  • Tyrothricin can additionally be incorporated into the cream of Example 10 in a known manner in an amount of 0.1% by weight.
  • Clotrimazole in an amount of 1% by weight can additionally be incorporated into the cream of Example 10 in a known manner.
  • betamethasone can additionally be incorporated in a known manner in an amount of 0.1% by weight.
  • Cetearyl Alcohol (Lanette 0) 2,000 mineral oil, DAB 9 20,000 paraben mixture as desired, magnesium sulfate (MgSO * 7 H 2 0) 0.700 combination A '+' D + F 'A': 14.30
  • Distearyldimethylammonium chloride (Genamin DS AC) 5,000 petroleum jelly, DAB 9 5,000 isopropyl palmitate 2,000 cetyl alcohol 1,000 silicone oil 0.100 propyl paraben 0.100 methyl paraben 0.100 glycerol 4,000
  • Glycerol monococoate polyoxyethylated with 7 mol ethylene oxide ("Cetiol HE" Henkel KGaA) 100.0 ethanol 65.0
  • a sun gel is produced in the usual way with the components mentioned.
  • a hydrogel is produced in the usual way with the constituents mentioned.
  • the fat bodies are heated to 80 to 85 ° C.
  • the water soluble components are in water at 40 ° C dissolved, both phases mixed with vigorous stirring, and allowed to cool with moderate stirring.
  • Myristyl alcohol, polyoxypropylated with 3 moles of propylene oxide (Witconol APM", Witco) 185.0 g water 637.0 g
  • the emulsion is prepared according to the example above.
  • the emulsion is prepared in the same manner as described in Example 21.
  • Micro wax (Lunacera 11", filler) 10.0 g caprylic / capric acid triglyceride (“Miglyol-
  • Neutral oil ", Dynamit-Nobel) 20.0 g myristyl alcohol, polyoxypropylated with 3 mol
  • the emulsion is prepared in the same manner as described in Example 21.
  • the emulsion is prepared in the same manner as described in Example 21.
  • Vitamin E acetate 16.5 g trans - urocanic acid 7.0 g dimethyldistearylammonium chloride
  • Glycerin 4.0 g perfume, correctives, additives, stabilizers as desired
  • a hair conditioner is produced in the usual way with the specified ingredients.
  • the active ingredients and active ingredient combinations are dissolved in the aqueous phase or in the fat phase and processed further in a known manner.
  • Capsules containing the ingredients listed below are made according to known procedures. These are suitable for the treatment of the above-mentioned diseases in dosage amounts of one capsule once or several times a day.
  • the effectiveness of the active substances and active systems according to the invention was demonstrated experimentally by means of chemiluminescence measurement in vivo on the back of the hand previously treated with verum (preparations with active substances according to the invention) or contralaterally with the respective vekicle.
  • the oxidative, radical processes in the treated skin areas were induced by UVA radiation (dose 500 mJ / cm).
  • the photons emitted by the skin are counted with a chemiluminescence measuring device suitable for in vivo measurements (counts / 2 min.).
  • a reduction in the emitted photon counts on the areas treated with verum compared to the areas treated with vehicles serves as evidence of the in vivo effectiveness of the preparations according to the invention.
  • measurements of active substances and preparations can also be carried out in vitro according to the same measuring principle.
  • the measured values (arithmetic mean values of the preparation according to the invention of example 10 are listed: verum 3054 counts / 2 min .; vehicle: 27278 counts / 2 min.
  • the effect according to the invention on the regulation and reconstitution of the glutathione status was e.g. histologically determined in the skin treated according to the invention on the basis of freshly obtained skin biopsies using the literature-described fluorescence detection method with the indicator monochlorobimane.
  • the quantitative evaluation was carried out on histological specimens using a microscope-coupled image analysis system.
  • the invention furthermore relates to compositions or preparations, in particular dermatological and cosmetic preparations, and particularly preferably topical preparations with the antioxidants and active substances according to the invention, in particular for the treatment of the indicated skin conditions and diseases.
  • the invention also relates to the use of the substances according to the invention for the production of compositions, in particular for the treatment of the skin conditions and diseases according to the invention.
  • agents, combinations and antioxidants and active substances according to the invention are outstandingly suitable for prophylaxis and treatment for the indicated indications. Furthermore, they allow, for example, a dose reduction when antimicrobial agents or corticosteroids are administered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

On utilise un ou plusieurs composés du groupe des antioxydants et/ou une ou plusieurs substances actives du groupe des substances actives qui régulent le métabolisme endogène d'énergie et/ou le système antioxydant enzymatique endogène, notamment celui de la peau, à un niveau normal, ou le maintiennent à un niveau normal, pour prévenir et pour traiter des états de sensibilité, d'hyperréactivité et de prédisposition de la peau aux dermatites, des formes d'acné, des états déficitaires ou hypoactifs de la peau dus au vieillissement et des dermatites atopiques manifestes telles que la dermatite atopique, la neurodermite, l'eczéma atopique et la séborrhée sèche, ainsi que des dermatoses induites par la lumière telles que la photodermatose polymorphe, l'acné de Mallorca, la photodermatite et des formes de prurigo, de prurit, de psoriasis, la couperose, l'ichtyose et des infections virales telles que l'herpès simplex, l'herpès zoster ou l'herpès labialis.
PCT/EP1994/002831 1993-08-27 1994-08-26 Agent de traitement d'etats de sensibilite, d'hyperreactivite et d'hypoactivite de la peau, de formes d'acne, de dermatites atopiques, du psoriasis, du prurigo, de photodermatoses, de l'ichtyose et d'infections virales WO1995005852A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94925480A EP0721347A1 (fr) 1993-08-27 1994-08-26 Agent de traitement d'etats de sensibilite, d'hyperreactivite et d'hypoactivite de la peau, de formes d'acne, de dermatites atopiques, du psoriasis, du prurigo, de photodermatoses, de l'ichtyose et d'infections virales
JP7507355A JPH09501925A (ja) 1993-08-27 1994-08-26 感受性が高い、過剰反応性の、そして低活性の皮膚状態、アクネの形態、アトピー性皮膚炎、乾癬、痒疹、光線皮膚病、魚鱗癬及びウイルス感染症に対する物質類

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4328871A DE4328871A1 (de) 1993-08-27 1993-08-27 Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis
DEP4328871.5 1993-08-27

Publications (1)

Publication Number Publication Date
WO1995005852A1 true WO1995005852A1 (fr) 1995-03-02

Family

ID=6496185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002831 WO1995005852A1 (fr) 1993-08-27 1994-08-26 Agent de traitement d'etats de sensibilite, d'hyperreactivite et d'hypoactivite de la peau, de formes d'acne, de dermatites atopiques, du psoriasis, du prurigo, de photodermatoses, de l'ichtyose et d'infections virales

Country Status (4)

Country Link
EP (1) EP0721347A1 (fr)
JP (1) JPH09501925A (fr)
DE (1) DE4328871A1 (fr)
WO (1) WO1995005852A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110628A (ja) * 1995-09-19 1997-04-28 L'oreal Sa 脂漏症を処理するための活性剤としてアスコルビン酸を含む化粧用および／または皮膚科学用組成物
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
GB2320431A (en) * 1996-12-20 1998-06-24 Johnson & Johnson Medical N-acetylcysteine for the treatment of chronic wounds
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
EP0728468A3 (fr) * 1995-02-26 2000-07-19 Unilever Plc Compositions cosmétiques pour traiter les demangeousons de la peau
WO2001049250A2 (fr) * 1999-12-30 2001-07-12 Perricone Nicholas V Traitement de l'acne a l'aide d'acide lipoique
WO2001068675A2 (fr) * 2000-03-17 2001-09-20 Seatek Marine Biotechnology Inc. Traitement de l'acne rosacee
WO2001085156A1 (fr) * 2000-05-09 2001-11-15 Kaneka Corporation Compositions dermiques ayant la coenzyme q comme principe actif
EP1371370A1 (fr) * 2001-03-21 2003-12-17 Eisai Co., Ltd. Medicaments a base de vitamine b2 reduite
US20040029969A1 (en) * 2000-07-06 2004-02-12 Beiersdorf Ag Use of creatine or creatine derivatives in cosmetic or dematological preparations
US6743433B2 (en) 2001-07-06 2004-06-01 Nicholas V. Perricone Treatment of acne using alkanolamine compositions
DE102004002602A1 (de) * 2004-01-15 2005-08-04 Beiersdorf Ag Visualisierung von Sonnenschutzmitteln auf der Haut
US7537752B2 (en) 2001-04-23 2009-05-26 L'oreal Use of a composition containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin
WO2018059787A1 (fr) * 2016-09-30 2018-04-05 Henkel Ag & Co. Kgaa Produits de soin capillaire conditionneurs assurant une protection contre la perte de couleur contenant un aldéhyde alpha-substitué
WO2019105505A1 (fr) * 2017-12-01 2019-06-06 Wredenhagen, Harald Émulsion de soin pour la peau et utilisation associée
US20200139164A1 (en) * 2017-07-20 2020-05-07 Thomas Leibbrand Tyrothricin for use in the treatment or prophylaxis of body odour and preparations therefor
US10751267B2 (en) 2016-12-21 2020-08-25 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
WO2021009164A1 (fr) * 2019-07-16 2021-01-21 Universiteit Gent Extrait de plantes pour lutter contre les nématodes parasites
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US11198724B2 (en) * 2013-03-14 2021-12-14 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
WO2022029785A1 (fr) * 2020-08-06 2022-02-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oléylcystéinamide ou dérivés de celui-ci et leurs utilisations en thérapie
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
US11540984B2 (en) 2018-05-23 2023-01-03 Conopco, Inc. Nanoemulsions and a method for making the same

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
DE19518845A1 (de) * 1995-05-23 1996-11-28 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Phytinsäure
DE19518815A1 (de) * 1995-05-23 1996-11-28 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an alpha-Hydroxyfettsäuren
DE19533330A1 (de) * 1995-09-11 1997-03-13 Beiersdorf Ag Gegen Hautkrebs wirksame topische Zubereitungen
DE19615575A1 (de) * 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Glucosiden und Ferulasäure als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
IT1282778B1 (it) * 1996-05-31 1998-03-31 Giorgio Panin Vitamina "e" acetato quale prodotto per applicazione topica
CA2209690A1 (fr) * 1996-07-31 1998-01-31 Sachiko Matsuura Medicament pour le traitement de l'acne commune
DE19651058A1 (de) * 1996-12-09 1998-06-10 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Tricaprylin
DE19651055B4 (de) * 1996-12-09 2006-03-16 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Dimethylisosorbid und deren Verwendung
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
DE69825288D1 (de) * 1997-08-07 2004-09-02 Univ Utah Prodrugs und konjugate von selenolenthaltenden verbindungen und ihre verwendung
FR2767692B1 (fr) * 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
FR2779060B1 (fr) 1998-05-26 2003-05-02 Oreal Association d'un retinoide avec un derive d'histidine
DE19903241A1 (de) * 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
US6455055B1 (en) 1999-02-12 2002-09-24 The Procter & Gamble Company Cosmetic compositions
US6309657B2 (en) 1999-02-12 2001-10-30 The Procter & Gamble Company Cosmetic compositions
US6224888B1 (en) 1999-02-12 2001-05-01 The Procter & Gamble Company Cosmetic compositions
IT1312377B1 (it) * 1999-03-05 2002-04-15 Uni Ci S R L Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
AUPQ515000A0 (en) * 2000-01-19 2000-02-10 Grigg, Geoffrey Walter Treatment of uv induced immunosuppression
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
DE10111040A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus alpha-Liponsäure und dermatologisch verträglichen Substanzen, die Lichtabsorption im UV-A-Bereich und/oder UV-B-Bereich zeigen, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
WO2002072040A1 (fr) * 2001-03-13 2002-09-19 Ajinomoto Co., Inc. Produits cosmetiques ou preparations a usage externe pour la peau
DE10130963A1 (de) * 2001-06-27 2003-01-16 Beiersdorf Ag Verwendung von Bis-Resorcinyltriazinderivaten zur Verbesserung der Wirksamkeit von lipophilen Wirkstoffen in kosmetischen oder dermatologischen Zubereitungen
DE10133202A1 (de) * 2001-07-07 2003-01-16 Beiersdorf Ag Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10147186A1 (de) * 2001-09-25 2003-04-24 Beiersdorf Ag Wirkstoffkombinationen aus Polyhexamethylenbiguanid-Hydrochlorid und Distearyldimethylammoniumchlorid und Zubereitungen, solche Wirkstoffkombinationen enthaltend
EP1297830A1 (fr) * 2001-09-28 2003-04-02 Flamma Fabbrica Lombarda Ammino Acidi S.p.a. L'utilisation des acides aminés alpha ou bèta, leurs esters, ou de dipeptides de ces acides aminés avec des dérivés d'histidine, dans la prévention ou le traitement de lésions de la peau causées par l'ozone atmosphérique
US20040147452A1 (en) * 2002-07-31 2004-07-29 Yu Ruey J Non-amphoteric glutathione derivative compositions for tropical application
JP4634027B2 (ja) * 2003-05-16 2011-02-16 花王株式会社 ビタミンｄ様活性代替用剤
CA2525465A1 (fr) * 2003-05-16 2004-11-25 Lotus Pharmaceutical Co., Ltd. Composition topique administree par voie percutanee
FR2857266B1 (fr) * 2003-07-07 2007-09-21 Jean Noel Thorel Composition a usage dermatologique et/ou cosmetique, comprenant a titre de principe actif au moins un antioxydant lipophile
JP2008037753A (ja) * 2004-12-06 2008-02-21 Mitsubishi Pharma Corp 掻痒の治療及び／又は予防剤
JP5102944B2 (ja) * 2005-06-08 2012-12-19 ロート製薬株式会社 皮膚外用剤
DE102006038449A1 (de) * 2006-06-08 2007-12-13 Henkel Kgaa Oxidative Haarbehandlung mit verringerter Haarschädigung
GB0803054D0 (en) * 2008-02-20 2008-03-26 Univ Manchester Medicament
FR2939041A1 (fr) * 2008-11-28 2010-06-04 Natura Cosmeticos Sa Melange hydratant, compositions cosmetiques et/ou pharmaceutiques le contenant et utilisation et methode de traitement cosmetique mettant en oeuvre ce melange
RU2605330C2 (ru) * 2010-10-27 2016-12-20 Нестек С.А. Способы и композиции, подходящие для укрепления здоровья кожи
WO2012101639A2 (fr) * 2011-01-24 2012-08-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticules pour l'administration dermique et systémique de médicaments
FI126259B (fi) 2011-02-11 2016-09-15 Upm Kymmene Corp Mikrofibrilloitu selluloosa käytettäväksi erityisesti atooppisen ihotulehduksen ja psoriasiksen hoidossa
ITMI20120268A1 (it) * 2012-02-23 2013-08-24 N G C Medical S P A Composizione per trattamento topico singolo ed in combinazione con sistemico, per rallentare l'invecchiamento cutaneo.
PL404174A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Zastosowanie pochodnych aminowych jako inhibitorów aktywności interleukiny 15
EP2939650A1 (fr) * 2014-04-29 2015-11-04 LTS LOHMANN Therapie-Systeme AG Pansement pour le traitement de dermatite
RS64310B1 (sr) * 2016-02-22 2023-07-31 Outplay Inc Kompozicija za topikalnu upotrebu bazirana na karnozin-magnezijum kompleksu
KR20180021280A (ko) * 2016-08-18 2018-03-02 한양대학교 산학협력단 리보플라빈을 포함하는 가려움증 억제 또는 완화용 조성물
RU2709502C1 (ru) * 2019-09-23 2019-12-18 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения
CN114699418A (zh) * 2022-04-02 2022-07-05 遵义医科大学 芦丁治疗银屑病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014412A1 (fr) * 1992-12-18 1994-07-07 Beiersdorf Ag Combinaisons synergiques de principes actifs pour les soins cosmetiques ou dermatologiques de la peau ou des elements tegumentaires

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859436A (en) * 1968-10-02 1975-01-07 Kolmar Laboratories Sugar composition for topical application
CH656067A5 (de) * 1981-12-10 1986-06-13 Richardson Vicks Inc Kosmetisches haarpflege- oder hautpflegemittel.
DE3382087D1 (de) * 1982-09-17 1991-02-07 Human Oltoanyagtermelo Praeparate zur behandlung von wunden der hautoberflaeche und verfahren zur herstellung derartiger praeparate.
DE3504695A1 (de) * 1985-02-12 1986-08-14 Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail Haarwuchsmittel
SU1486168A1 (ru) * 1985-07-30 1989-06-15 Proizv Ob Biokhimreaktiv N Биологически активная добавка для косметических средств
FR2647342B1 (fr) * 1989-05-23 1994-05-27 Sanofi Sa Composition cosmetique s'opposant au vieillissement de la peau
CH679981A5 (fr) * 1989-12-21 1992-05-29 Paul Dr Med Herzog
GB9006785D0 (en) * 1990-03-27 1990-05-23 Leung Lit Hung Composition and methods for treatment of acne vulgaris and retardation of ageing
EP0536311A4 (en) * 1990-06-21 1993-05-19 Trustees Of Boston University Compositions comprising vitamin d precursors, analogs thereof and their use
GB9015774D0 (en) * 1990-07-18 1990-09-05 Leo Pharm Prod Ltd Novel treatment
AU649057B2 (en) * 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
KR950007045B1 (ko) * 1992-04-14 1995-06-30 주식회사태평양 폴리에톡실레이티드 비타민 e를 함유한 피부화장료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014412A1 (fr) * 1992-12-18 1994-07-07 Beiersdorf Ag Combinaisons synergiques de principes actifs pour les soins cosmetiques ou dermatologiques de la peau ou des elements tegumentaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HELLWIG ; OTTO: "Arzneimittel", 1992, WISSENSCHAFTLICHE VERLAGSGESELLSCHAFT MBH, STUTTGART *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728468A3 (fr) * 1995-02-26 2000-07-19 Unilever Plc Compositions cosmétiques pour traiter les demangeousons de la peau
JPH09110628A (ja) * 1995-09-19 1997-04-28 L'oreal Sa 脂漏症を処理するための活性剤としてアスコルビン酸を含む化粧用および／または皮膚科学用組成物
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
US6166084A (en) * 1996-12-20 2000-12-26 Johnson & Johnson Medical, Ltd. Compositions for the treatment of chronic wounds
GB2320431A (en) * 1996-12-20 1998-06-24 Johnson & Johnson Medical N-acetylcysteine for the treatment of chronic wounds
GB2320431B (en) * 1996-12-20 2000-08-30 Johnson & Johnson Medical Compositions for the treatment of chronic wounds
US6365623B1 (en) * 1997-11-17 2002-04-02 Nicholas V. Perricone Treatment of acne using lipoic acid
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
WO2001049250A2 (fr) * 1999-12-30 2001-07-12 Perricone Nicholas V Traitement de l'acne a l'aide d'acide lipoique
WO2001049250A3 (fr) * 1999-12-30 2002-01-10 Nicholas V Perricone Traitement de l'acne a l'aide d'acide lipoique
WO2001068675A2 (fr) * 2000-03-17 2001-09-20 Seatek Marine Biotechnology Inc. Traitement de l'acne rosacee
WO2001068675A3 (fr) * 2000-03-17 2001-12-13 Seatek Marine Biotechnology In Traitement de l'acne rosacee
US7153826B2 (en) 2000-03-17 2006-12-26 Seatek Marine Biotechnology, Inc. Treatment of rosacea
WO2001085156A1 (fr) * 2000-05-09 2001-11-15 Kaneka Corporation Compositions dermiques ayant la coenzyme q comme principe actif
US20040029969A1 (en) * 2000-07-06 2004-02-12 Beiersdorf Ag Use of creatine or creatine derivatives in cosmetic or dematological preparations
EP1371370A1 (fr) * 2001-03-21 2003-12-17 Eisai Co., Ltd. Medicaments a base de vitamine b2 reduite
EP1371370B1 (fr) * 2001-03-21 2009-09-09 Eisai R&D Management Co., Ltd. Medicaments a base de vitamine b2 reduite
US7579325B2 (en) 2001-03-21 2009-08-25 Eisai R & D Management Co., Ltd. Drugs containing reduced of vitamin B2
US7537752B2 (en) 2001-04-23 2009-05-26 L'oreal Use of a composition containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin
US7125882B2 (en) 2001-07-06 2006-10-24 Union Bank Of California, N.A. Treatment of acne using alkonolamine compositions
US6743433B2 (en) 2001-07-06 2004-06-01 Nicholas V. Perricone Treatment of acne using alkanolamine compositions
US7081479B2 (en) 2001-07-06 2006-07-25 Perricone Nicholas V Treatment of acne using alkonolamine compositions
DE102004002602A1 (de) * 2004-01-15 2005-08-04 Beiersdorf Ag Visualisierung von Sonnenschutzmitteln auf der Haut
US11198724B2 (en) * 2013-03-14 2021-12-14 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
US12065485B2 (en) 2013-03-14 2024-08-20 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
WO2018059787A1 (fr) * 2016-09-30 2018-04-05 Henkel Ag & Co. Kgaa Produits de soin capillaire conditionneurs assurant une protection contre la perte de couleur contenant un aldéhyde alpha-substitué
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US10980718B2 (en) 2016-12-21 2021-04-20 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US10751267B2 (en) 2016-12-21 2020-08-25 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
US11596586B2 (en) 2016-12-21 2023-03-07 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11666519B2 (en) 2016-12-21 2023-06-06 Conopco, Inc. Personal care compositions with cystine
US11759412B2 (en) 2016-12-21 2023-09-19 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US20200139164A1 (en) * 2017-07-20 2020-05-07 Thomas Leibbrand Tyrothricin for use in the treatment or prophylaxis of body odour and preparations therefor
WO2019105505A1 (fr) * 2017-12-01 2019-06-06 Wredenhagen, Harald Émulsion de soin pour la peau et utilisation associée
US11540984B2 (en) 2018-05-23 2023-01-03 Conopco, Inc. Nanoemulsions and a method for making the same
WO2021009164A1 (fr) * 2019-07-16 2021-01-21 Universiteit Gent Extrait de plantes pour lutter contre les nématodes parasites
WO2022029785A1 (fr) * 2020-08-06 2022-02-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oléylcystéinamide ou dérivés de celui-ci et leurs utilisations en thérapie

Also Published As

Publication number Publication date
DE4328871A1 (de) 1995-03-02
EP0721347A1 (fr) 1996-07-17
JPH09501925A (ja) 1997-02-25

Similar Documents

Publication Publication Date Title
WO1995005852A1 (fr) Agent de traitement d'etats de sensibilite, d'hyperreactivite et d'hypoactivite de la peau, de formes d'acne, de dermatites atopiques, du psoriasis, du prurigo, de photodermatoses, de l'ichtyose et d'infections virales
EP0797427B1 (fr) Agents efficaces contre des etats cutanes deficients hyper-reactifs ou hypo-actifs et des dermatites manifestes
EP0751761B1 (fr) Substances actives et compositions pour le traitement du xerosis des personnes agees
EP0859592B1 (fr) Produit de soin pour la senescence cutanee
EP1305003B1 (fr) Utilisation d'une combinaison d'agents activs contenatn des bioquinones pour la preparation d'une composition dosmetiques ou dermatologique pour le traitement ou la prevention des pellicules
EP0688210B1 (fr) Utilisation de carnosine en combinaison avec l'acide urocanique pour le traitement des photodermatoses
DE4420625C1 (de) Wirkstoffkombination mit einem Gehalt an Glycerylalkylethern und kosmetische und dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
US20110070213A1 (en) Dermal compositions containing coenzyme q as the active ingredient
JPH09505822A (ja) Ｌ−アルギニン、ｌ−オルニチン又はｌ−シトルリン及びこれらの物質の局所用調製物類の使用
DE10032964A1 (de) Verwendung von Kreatin und/oder Kreatingderivaten in kosmetischen oder dermatologischen Zubereitungen
EP1623698A1 (fr) Utilisation d'une combinaison comprenant au moins un bioquinone et au moins un isoflavanoïde pour améliorer l'état de la peau
CN112641670A (zh) 保湿精华乳及其制备方法
DE60133038T2 (de) Hypoallergenisches nichtreizendes hautpflegemittel
EP2769709A1 (fr) Mélange complexe de pseudo-lipide et composition pour application externe cutanée contenant celui-ci
DE19533330A1 (de) Gegen Hautkrebs wirksame topische Zubereitungen
DE10128910A1 (de) Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
US20040081674A1 (en) Hypoallergenic and non-irritant skin care formulations
EP0656773B1 (fr) Utilisation de capteurs de radicaux comme agents immunomodulateurs dans des compositions cosmetiques et dermatologiques
EP1046392A2 (fr) Compositions cosmétiques et dermatologiques pour améliorer la fonction de barrièrre de la peau
JP2003081741A (ja) 皮膚外用剤
DE102020125874A1 (de) Zusammensetzung zur Behandlung von Haaren und der Haut
DE10316666B4 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
KR100578446B1 (ko) 마이크론화된 우레아를 포함하는 수분 무함유 피부 보호제제 및 그의 제조 방법
US20040116531A1 (en) Water-free skin care formulations comprising micronized urea and method of manufacturing the same
WO2023194557A1 (fr) Composition pour le traitement de la peau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994925480

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 604961

Date of ref document: 19960226

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1994925480

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994925480

Country of ref document: EP